vs
Fulgent Genetics, Inc.（FLGT）与Ribbon Communications Inc.（RBBN）财务数据对比。点击上方公司名可切换其他公司
Ribbon Communications Inc.的季度营收约是Fulgent Genetics, Inc.的2.0倍（$162.6M vs $83.3M），Ribbon Communications Inc.净利率更高（54.8% vs -28.1%，领先82.9%），Fulgent Genetics, Inc.同比增速更快（9.3% vs -10.3%），过去两年Fulgent Genetics, Inc.的营收复合增速更高（13.7% vs -8.1%）
Fulgent Genetics是一家分子诊断技术企业，开发并提供覆盖携带者筛查、肿瘤基因检测、传染病检测、遗传性疾病分析的多元基因检测服务，主要客户为北美地区的医疗机构、药企、科研院所及公共卫生组织。
睿宾通信公司（Ribbon Communications Inc.）主要为电信运营商、企业及关键基础设施领域提供软件、IP与光网络解决方案。公司于2017年由Genband与Sonus Networks合并成立，总部位于美国得克萨斯州普莱诺，是一家上市科技企业。
FLGT vs RBBN — 直观对比
营收规模更大
RBBN
是对方的2.0倍
$83.3M
营收增速更快
FLGT
高出19.6%
-10.3%
净利率更高
RBBN
高出82.9%
-28.1%
两年增速更快
FLGT
近两年复合增速
-8.1%
损益表 — Q4 FY2025 vs Q1 FY2026
| 指标 | | |
|---|---|---|
| 营收 | $83.3M | $162.6M |
| 净利润 | $-23.4M | $89.1M |
| 毛利率 | 39.1% | 42.9% |
| 营业利润率 | -43.5% | 37.6% |
| 净利率 | -28.1% | 54.8% |
| 营收同比 | 9.3% | -10.3% |
| 净利润同比 | -297.7% | — |
| 每股收益（稀释后） | — | $0.50 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收FLGTRBBN
| Q1 26 | — | $162.6M | ||
| Q4 25 | $83.3M | $227.3M | ||
| Q3 25 | $84.1M | $215.4M | ||
| Q2 25 | $81.8M | $220.6M | ||
| Q1 25 | $73.5M | $181.3M | ||
| Q4 24 | $76.2M | $251.4M | ||
| Q3 24 | $71.7M | $210.2M | ||
| Q2 24 | $71.0M | $192.6M |
净利润FLGTRBBN
| Q1 26 | — | $89.1M | ||
| Q4 25 | $-23.4M | — | ||
| Q3 25 | $-6.6M | $-12.1M | ||
| Q2 25 | $-19.0M | $-11.1M | ||
| Q1 25 | $-11.5M | $-26.2M | ||
| Q4 24 | $-5.9M | — | ||
| Q3 24 | $-14.6M | $-13.4M | ||
| Q2 24 | $-8.7M | $-16.8M |
毛利率FLGTRBBN
| Q1 26 | — | 42.9% | ||
| Q4 25 | 39.1% | 53.3% | ||
| Q3 25 | 42.2% | 50.1% | ||
| Q2 25 | 42.1% | 49.6% | ||
| Q1 25 | 38.6% | 45.4% | ||
| Q4 24 | 41.8% | 55.7% | ||
| Q3 24 | 37.3% | 52.1% | ||
| Q2 24 | 37.3% | 50.8% |
营业利润率FLGTRBBN
| Q1 26 | — | 37.6% | ||
| Q4 25 | -43.5% | 4.1% | ||
| Q3 25 | -18.3% | 1.3% | ||
| Q2 25 | -24.1% | 1.9% | ||
| Q1 25 | -26.9% | -10.8% | ||
| Q4 24 | -21.2% | 13.2% | ||
| Q3 24 | -23.8% | -0.4% | ||
| Q2 24 | -26.6% | -1.0% |
净利率FLGTRBBN
| Q1 26 | — | 54.8% | ||
| Q4 25 | -28.1% | — | ||
| Q3 25 | -7.9% | -5.6% | ||
| Q2 25 | -23.2% | -5.0% | ||
| Q1 25 | -15.7% | -14.5% | ||
| Q4 24 | -7.7% | — | ||
| Q3 24 | -20.4% | -6.4% | ||
| Q2 24 | -12.3% | -8.7% |
每股收益（稀释后）FLGTRBBN
| Q1 26 | — | $0.50 | ||
| Q4 25 | — | $0.50 | ||
| Q3 25 | — | $-0.07 | ||
| Q2 25 | — | $-0.06 | ||
| Q1 25 | — | $-0.15 | ||
| Q4 24 | — | $0.05 | ||
| Q3 24 | — | $-0.08 | ||
| Q2 24 | — | $-0.10 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $50.2M | $67.6M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $1.1B | $419.1M |
| 总资产 | $1.2B | — |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资FLGTRBBN
| Q1 26 | — | $67.6M | ||
| Q4 25 | $50.2M | $96.4M | ||
| Q3 25 | $117.6M | $74.8M | ||
| Q2 25 | $87.9M | $60.5M | ||
| Q1 25 | $67.3M | $71.2M | ||
| Q4 24 | $55.1M | $87.8M | ||
| Q3 24 | $58.0M | $37.2M | ||
| Q2 24 | $65.1M | $64.6M |
总债务FLGTRBBN
| Q1 26 | — | — | ||
| Q4 25 | — | $342.1M | ||
| Q3 25 | — | $344.3M | ||
| Q2 25 | — | $346.5M | ||
| Q1 25 | — | $347.4M | ||
| Q4 24 | — | $348.3M | ||
| Q3 24 | — | $349.1M | ||
| Q2 24 | — | $350.0M |
股东权益FLGTRBBN
| Q1 26 | — | $419.1M | ||
| Q4 25 | $1.1B | $449.0M | ||
| Q3 25 | $1.1B | $360.1M | ||
| Q2 25 | $1.1B | $370.4M | ||
| Q1 25 | $1.1B | $381.8M | ||
| Q4 24 | $1.1B | $404.6M | ||
| Q3 24 | $1.1B | $395.5M | ||
| Q2 24 | $1.1B | $405.0M |
总资产FLGTRBBN
| Q1 26 | — | — | ||
| Q4 25 | $1.2B | $1.2B | ||
| Q3 25 | $1.2B | $1.1B | ||
| Q2 25 | $1.2B | $1.1B | ||
| Q1 25 | $1.2B | $1.1B | ||
| Q4 24 | $1.2B | $1.2B | ||
| Q3 24 | $1.2B | $1.1B | ||
| Q2 24 | $1.2B | $1.1B |
负债/权益比FLGTRBBN
| Q1 26 | — | — | ||
| Q4 25 | — | 0.76× | ||
| Q3 25 | — | 0.96× | ||
| Q2 25 | — | 0.94× | ||
| Q1 25 | — | 0.91× | ||
| Q4 24 | — | 0.86× | ||
| Q3 24 | — | 0.88× | ||
| Q2 24 | — | 0.86× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-78.1M | — |
| 自由现金流经营现金流 - 资本支出 | $-83.1M | — |
| 自由现金流率自由现金流/营收 | -99.7% | — |
| 资本支出强度资本支出/营收 | 6.0% | — |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | $-124.2M | — |
8季度趋势，按日历期对齐
经营现金流FLGTRBBN
| Q1 26 | — | — | ||
| Q4 25 | $-78.1M | $29.2M | ||
| Q3 25 | $11.1M | $26.5M | ||
| Q2 25 | $-30.2M | $-795.0K | ||
| Q1 25 | $-4.4M | $-3.5M | ||
| Q4 24 | $25.0M | $61.8M | ||
| Q3 24 | $-15.5M | $-14.8M | ||
| Q2 24 | $4.3M | $-9.8M |
自由现金流FLGTRBBN
| Q1 26 | — | — | ||
| Q4 25 | $-83.1M | $27.3M | ||
| Q3 25 | $5.1M | $21.0M | ||
| Q2 25 | $-37.0M | $-6.5M | ||
| Q1 25 | $-9.1M | $-15.7M | ||
| Q4 24 | $21.2M | $53.8M | ||
| Q3 24 | $-35.0M | $-23.7M | ||
| Q2 24 | $-8.7M | $-12.9M |
自由现金流率FLGTRBBN
| Q1 26 | — | — | ||
| Q4 25 | -99.7% | 12.0% | ||
| Q3 25 | 6.0% | 9.7% | ||
| Q2 25 | -45.2% | -2.9% | ||
| Q1 25 | -12.5% | -8.7% | ||
| Q4 24 | 27.9% | 21.4% | ||
| Q3 24 | -48.8% | -11.3% | ||
| Q2 24 | -12.2% | -6.7% |
资本支出强度FLGTRBBN
| Q1 26 | — | — | ||
| Q4 25 | 6.0% | 0.9% | ||
| Q3 25 | 7.2% | 2.6% | ||
| Q2 25 | 8.3% | 2.6% | ||
| Q1 25 | 6.4% | 6.7% | ||
| Q4 24 | 5.0% | 3.2% | ||
| Q3 24 | 27.2% | 4.2% | ||
| Q2 24 | 18.2% | 1.6% |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
FLGT
| Precision Diagnostics | $48.3M | 58% |
| Anatomic Pathology | $27.0M | 32% |
| Biopharma Services | $7.8M | 9% |
RBBN
| Service | $94.5M | 58% |
| Product | $68.1M | 42% |
